commande domperidone domperidone sans recette http://www.cricyt.edu.ar/?size=695404&pr... nizoral generic http://www.smwc.edu/?size=2718&price=271... http://www.smwc.edu/?size=582993&price=5...
http://kanab.utah.gov/licence.php?int=25... http://kanab.utah.gov/licence.php?int=27... buy finasteride
acheter actos online acheter pentasa online strattera sans ordonnance
comparatif cialis viagra cialis levitra generika viagra en pocos dias viagra lääke cialis belgique allemagne viagra 1 euro
    vente levitra achar viagra par internet espagne vente viagra en ligne
    generika finasterid clomid preis prix boite viagra

Tag Archive | "paclitaxel"

Plasmonic nanobubbles can detect and kill only cancer cells

Tuesday, June 3, 2014

0 Comments

Source: www.azonano.com Author: staff The first preclinical study of a new Rice University-developed anti-cancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells — often by blowing them apart — without harming surrounding normal organs. The research, which is available online this week Nature Medicine, reports […]

Continue reading...

Low-dose IMRT may be safe for patients with HPV-positive head and neck cancer

Tuesday, June 3, 2014

0 Comments

Source: www.oncologypractice.com Author: Laura Nikolaides Lower-dose radiation therapy may be safe for some patients with human papillomavirus (HPV)-positive oropharyngeal cancer, decreasing the risk of often long-term side effects, such as trouble swallowing, dry mouth, loss of taste, neck stiffness, and thyroid problems, investigators reported at the annual meeting of the American Society of Clinical Oncology. […]

Continue reading...

Positive data announced for Reolysin in head and neck cancers

Sunday, December 23, 2012

0 Comments

Source: www.empr.com Author: staff Oncolytics Biotech announced positive top line data in its double-blinded randomized Phase 3 clinical study examining Reolysin in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers. Reolysin is a proprietary formulation of the human reovirus. A first analysis compared the relative percentages of patients […]

Continue reading...

Use of carbon nanoparticles paves way to customized cancer therapy

Sunday, February 19, 2012

0 Comments

Source: www.azonano.com Author: Cameron Chai A research study by Jeffrey Myers from the University of Texas MD Anderson Cancer Center and James Tour from the Rice University has reported that a combination of carbon nanoparticles and existing drugs has the capability to improve head-and-neck cancer treatment, particularly when coupled with radiation therapy.   The novel […]

Continue reading...

Taking out a cancer’s co-dependency: novel compound selectively kills cancer cells by blocking response to oxidative stress

Wednesday, July 20, 2011

0 Comments

Source: www.eurekalert.org Author: public release A cancer cell may seem out of control, growing wildly and breaking all the rules of orderly cell life and death. But amid the seeming chaos there is a balance between a cancer cell’s revved-up metabolism and skyrocketing levels of cellular stress. Just as a cancer cell depends on a […]

Continue reading...

Plant stem cells pave way for low-cost cancer drug

Tuesday, October 26, 2010

0 Comments

Source: sify.com Author: saff A new study has suggested that a well-known cancer drug could be produced cheaply and sustainably using stem cells derived from trees. University of Edinburgh researchers have isolated and grown stem cells from a yew tree whose bark is a natural source of the anticancer compound paclitaxel. The development could enable […]

Continue reading...

Neck response to chemoradiotherapy

Tuesday, November 17, 2009

0 Comments

Source: Arch Otolaryngol Head Neck Surg. 2009;135(11):1133-1136 Author: Alexander Langerman, MD et al. Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer Objective: The role of neck dissection following chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer is an area of active debate. Patients who have a complete […]

Continue reading...

Oncolytics’ Phase III borrows adaptive design in SPA trial

Monday, October 5, 2009

0 Comments

Source: www.bioworld.com Author: Catherine Hollingsworth Oncolytics Biotech Inc. reached agreement with the FDA on the design of a Phase III trial of Reolysin in head and neck cancer, marking the first such agreement for an intravenously administered oncolytic virus. The Phase III trial will be conducted in two stages and will cost an estimated $15 […]

Continue reading...

Early postoperative Taxol® may improve outcomes in high-risk head and neck cancer

Sunday, September 13, 2009

0 Comments

Source: professional.cancerconsultants.com Author: staff Researchers involved in the RTOG 0024 study have reported that the administration of early adjuvant Taxol® (paclitaxel) followed by concurrent chemoradiotherapy may improve local control and improve disease-free survival in patients with high-risk head and neck carcinoma. The details of this study appeared in the Journal of Clinical Oncology early online […]

Continue reading...

Oncolytics Biotech(R) Inc. collaborators present positive head and neck results in phase I/II combination

Monday, March 23, 2009

0 Comments

Source: pr-canada.net Author: press release Oncolytics Biotech Inc. announced that interim clinical results from its Phase I/II U.K. trial of Reolysin(R) combined with paclitaxel/carboplatin for patients with advanced cancers were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is being held in Banff, Alberta from March 18th to 22nd, 2009. […]

Continue reading...